Based on the measurements of operating efficiency obtained from BioNexus Gene's historical financial statements, BioNexus Gene Lab may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, BioNexus Gene's Other Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 1.9 M, whereas Total Current Liabilities is forecasted to decline to about 1.5 M. Key indicators impacting BioNexus Gene's financial strength include:
Investors should never underestimate BioNexus Gene's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BioNexus Gene's cash flow, debt, and profitability to make informed and accurate decisions about investing in BioNexus Gene Lab.
Net Income
(2.5 Million)
BioNexus
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Net Borrowings
Free Cash Flow
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Change To Inventory
Investments
Change In Working Capital
Depreciation
Other Non Cash Items
Change To Account Receivables
Other Cashflows From Investing Activities
Dividends Paid
Total Current Liabilities
Net Tangible Assets
Retained Earnings
Other Stockholder Equity
Total Current Assets
Common Stock
Other Current Liab
Other Liab
Accounts Payable
Net Receivables
Inventory
Property Plant Equipment
Total Assets
Short Long Term Debt Total
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Total Liab
Net Invested Capital
Long Term Investments
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Short Term Debt
Non Currrent Assets Other
Short Term Investments
Other Current Assets
Property Plant And Equipment Gross
Interest Expense
Other Operating Expenses
Net Income Applicable To Common Shares
Ebit
Income Tax Expense
Tax Provision
Depreciation And Amortization
Selling General Administrative
Total Revenue
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Interest Income
Probability Of Bankruptcy
Understanding current and past BioNexus Gene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioNexus Gene's financial statements are interrelated, with each one affecting the others. For example, an increase in BioNexus Gene's assets may result in an increase in income on the income statement.
Please note, the presentation of BioNexus Gene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioNexus Gene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioNexus Gene's management manipulating its earnings.
BioNexus Gene Stock Summary
BioNexus Gene competes with Oil Dri, H B, Northern Technologies, and Cabot. BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming. Bionexus Gene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 27 people.
Comparative valuation techniques use various fundamental indicators to help in determining BioNexus Gene's current stock value. Our valuation model uses many indicators to compare BioNexus Gene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioNexus Gene competition to find correlations between indicators driving BioNexus Gene's intrinsic value. More Info.
BioNexus Gene Lab is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . At present, BioNexus Gene's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioNexus Gene's earnings, one of the primary drivers of an investment's value.
BioNexus Gene Lab Systematic Risk
BioNexus Gene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioNexus Gene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on BioNexus Gene Lab correlated with the market. If Beta is less than 0 BioNexus Gene generally moves in the opposite direction as compared to the market. If BioNexus Gene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioNexus Gene Lab is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioNexus Gene is generally in the same direction as the market. If Beta > 1 BioNexus Gene moves generally in the same direction as, but more than the movement of the benchmark.
About BioNexus Gene Financials
What exactly are BioNexus Gene Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include BioNexus Gene's income statement, its balance sheet, and the statement of cash flows. Potential BioNexus Gene investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although BioNexus Gene investors may use each financial statement separately, they are all related. The changes in BioNexus Gene's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioNexus Gene's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
Today, most investors in BioNexus Gene Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioNexus Gene's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BioNexus Gene growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(0.005712)
At present, BioNexus Gene's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
BioNexus Gene November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioNexus Gene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioNexus Gene Lab. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioNexus Gene Lab based on widely used predictive technical indicators. In general, we focus on analyzing BioNexus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioNexus Gene's daily price indicators and compare them against related drivers.
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.